A long-awaited coronavirus vaccine could be available in roughly two months, according to drugmaker AstraZeneca, which is developing a treatment.
The Anglo-Swedish drugmaker is working with the University of Oxford to develop one of the most closely watched COVID-19 vaccines, which is in late stage trials in the U.S., the U.K. and other countries to determine its safety and effectiveness. Once those results are reported, regulators will have to approve the vaccine for widespread use.
AstraZeneca said it will analyze data from its vaccine trials in November and December. If the results look promising, it will move quickly to ramp up manufacturing and obtain government approval in the U.S. and elsewhere, Chief Executive Pascal Soriot said Thursday.
LONDON — Germany was lauded for its initial response to the coronavirus pandemic, but a four-week long return to strict public health measures has raised questions over the effectiveness of its strategy second time around.
The UN General Assembly moved Thursday to hold a special session focused on international coordination to the coronavirus pandemic from December 3-4 in New York.
Discussed since June, the meeting is intended to bring together heads of state and government according to a resolution adopted by 150 of the 193 General Assembly members.
Recent Comments